We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| PTC Therapeutics Inc | NASDAQ:PTCT | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.05 | -0.15% | 32.96 | 30.65 | 34.50 | 33.32 | 32.54 | 32.96 | 468,720 | 22:30:00 |
From May 2022 to May 2024
By Colin Kellaher
PTC Therapeutics Inc. on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of its Upstaza gene-replacement therapy for the treatment of aromatic L-amino acid decarboxylase, or AADC, deficiency.
The South Plainfield, N.J., pharmaceutical company said Upstaza, if approved by the European Commission, would be the first disease-modifying treatment for the rare genetic disorder for patients 18 months and older and the first marketed gene therapy directly infused into the brain.
The European Commission, which generally follows the CHMP's advice, is expected to make a decision in about two months, PTC said.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 20, 2022 08:39 ET (12:39 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year PTC Therapeutics Chart |
1 Month PTC Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
